There are 2789 resources available
1219P - Study of anlotinib combined with icotinib as the first-line treatment in NSCLC patients harboring activating EGFR mutations: Updated results of ALTER-L004
Presenter: Dingzhi Huang
Session: ePoster Display
1220P - A randomized phase II trial of anlotinib plus docetaxel vs docetaxel for second-line treatment of EGFR-negative NSCLC (ALTER-L018)
Presenter: Lin Wu
Session: ePoster Display
1221P - Outcomes of EGFR-mutant NSCLC patients with de novo brain metastases by upfront treatment
Presenter: Jun Ma
Session: ePoster Display
1222P - A blood-based DNA methylation risk score (RS) for predicting the prognosis of EGFR mutation positive (EGFRm) advanced non-small cell lung cancer (NSCLC) after first-line TKI treatment
Presenter: Dongsheng Shi
Session: ePoster Display
1224P - Systematic review and meta-analysis of immunotherapy effectiveness for pretreated patients with non-small cell lung cancer harboring EGFR exon 20 insertions
Presenter: Petros Christopoulos
Session: ePoster Display
1226P - Efficacy and safety of Anti-EGFR TKIs combined with bevacizumab or ramucirumab in the first-line treatment of non-small cell lung cancer: Meta-analysis of randomized controlled trials
Presenter: Yakup Ergün
Session: ePoster Display